Figure 5.

Acute pharmacological blockade of CaN rescues reduced anxiety in Rcan1 KO mice. A, Time in each OFA zone following intraperitoneal FK506 treatment. Vehicle-treated Rcan1 KO mice spend more time in the center zone than periphery of the OFA compared with similarly treated WT controls, whereas FK506-treated Rcan1 KO mice are not different from vehicle-treated WT controls. B, FK506 treatment reduces distance traveled by both WT and Rcan1 KO mice in all zones of the OFA. C, Movement in the OFA plotted as a ratio of distance traveled in each zone (zone distance) to total distance traveled during the test period. Using this measure, vehicle-treated Rcan1 KO mice move significantly more than vehicle-treated WT littermates in the center zone, whereas FK506-treated KO mice are indistinguishable from vehicle-treated WT mice. D, EPM open-arm and closed-arm time following CsA treatment via intraventricular cannulation. Pairwise comparisons (Dunn's with Bonferroni) revealed significant effects between the WT and KO vehicle groups (p = 0.014) and between the KO CsA and vehicle treatment groups (p = 0.004), while there was no difference between KO-CsA and WT-vehicle groups (p = 0.505) or WT-CsA groups (p = 0.995). Center zone measurements are not included but there is no difference between the groups. E, Total distance moved in the EPM is similar for WT and Rcan1 KO mice following intracerebroventricular administration of CsA or vehicle. OFA: N = 12 KO-vehicle, 20 WT-vehicle, 9 KO-FK506, 9 WT-FK506; EPM: N = 7 KO-vehicle, 11 WT-vehicle, 7 KO-CsA, 10 WT-CsA. **p < 0.01; ***p < 0.001; n.s., p > 0.05.